Ranbaxy Shifts Lipitor Generic Production From U.S. To New India Plant
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories has begun transferring U.S. production of its generic version of Pfizer’s Lipitor (atorvastatin) cholesterol drug back home to India at its newly approved production facility in Mohali.
You may also be interested in...
Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
How Merck Plans To Protect Commercial Info Under EU Clinical Trial Rules
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
UK Supplements Marketer Makes No Effort To Back Up Ad Claims
The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.
Need a specific report? 1000+ reports available
Buy Reports